ArriVent BioPharma, Inc. Common Stock - Asset Resilience Ratio
ArriVent BioPharma, Inc. Common Stock (AVBP) has an Asset Resilience Ratio of 55.34% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ArriVent BioPharma, Inc. Common Stock short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how ArriVent BioPharma, Inc. Common Stock's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see AVBP total assets.
Liquid Assets Composition Over Time
This chart breaks down ArriVent BioPharma, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ArriVent BioPharma, Inc. Common Stock long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $218.44 Million | 55.34% |
| Total Liquid Assets | $218.44 Million | 55.34% |
Asset Resilience Insights
- Very High Liquidity: ArriVent BioPharma, Inc. Common Stock maintains exceptional liquid asset reserves at 55.34% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ArriVent BioPharma, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare ArriVent BioPharma, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for ArriVent BioPharma, Inc. Common Stock (2023–2025)
The table below shows the annual Asset Resilience Ratio data for ArriVent BioPharma, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-09-30 | 80.22% | $267.28 Million | $333.17 Million | +27.64pp |
| 2024-09-30 | 52.58% | $144.57 Million | $274.94 Million | -- |
| 2023-09-30 | 0.00% | $0.00 | $163.10 Million | -- |
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutati… Read more